Virtue® SAB

Strategic Partnership with Terumo Corporation for development and commercialization of Virtue® Sirolimus AngioInfusion Balloon

  • In June 2019, Orchestra BioMed entered into a collaborative agreement, pursuant to which Terumo secured global commercialization rights for Virtue SAB in coronary and peripheral vascular indications
  • Under the terms of the agreement, Terumo made a one-time, up-front payment and an equity commitment to Orchestra BioMed and will also make substantial future clinical and regulatory milestone payments to Orchestra BioMed
  • Terumo will assume financial and execution responsibility for substantially all of future clinical and regulatory development with the exception of the Virtue ISR-US trial. Terumo will also be responsible for device manufacturing, commercial sales, marketing and distribution for Virtue SAB globally
  • Orchestra BioMed will share meaningfully in future commercial revenues of Virtue SAB through royalties and per unit payments as the exclusive supplier of the proprietary SirolimusEFR formulation used in Virtue SAB
  • Orchestra BioMed retains the rights to develop and license technology used in Virtue SAB for clinical applications outside of coronary and peripheral vascular interventions

“This strategic partnership is a major milestone for Orchestra BioMed. It validates our differentiated strategy to focus on the development of high-impact therapies while leveraging alliances with established market leaders, like Terumo, to drive global commercialization of our products.”

– David Hochman, Chairman, CEO and Founder, Orchestra BioMed

Have a question?
Contact us at 917.254.4900 or info@orchestrabiomed.com